Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials

Suzanne Lentzsch, Nicolas Villanueva, MD, James Nguyen, BS, Heather Landau, MD, Nikoletta Lendvai, MDPhD, Susanna Miao, BA, Jordan M. Schecter, MD, Mariamne Reyna, BS, Markus Y Mapara, MD PhD, Robert L. Redner, MD, David J Chung, MDPhD, Alexander M. Lesokhin, MD, Tarun Kewalramani, MD, Sergio Giralt, MD, Raymond L. Comenzo, MD, Ola Landgren, MD PhD, Hani Hassoun, MD

Blood (2015) 126 (23): 1975.

https://doi.org/10.1182/blood.V126.23.1975.1975

Published: 2015

Journal Articles

Interim Analysis of a Randomized Phase II Trial Comparing Continuous Lenalidomide and Dexamethasone to Autologous Stem Cell Transplantation in Multiple Myeloma Patients Responsive to Lenalidomide and Dexamethasone Induction

Jonathan I Weltz, BA, Heather Landau, MD, Nikoletta Lendvai, MDPhD, David J Chung, MDPhD, Alexander M. Lesokhin, MD, Sean M. Devlin, PhD, Elyn Riedel, MA, Kaitlin M Woo, MA, Amanda Stellman, BA, Danielle Chimento, BA, Tarun Kewalramani, MD, Ola Landgren, MD PhD, Sergio Giralt, MD, Raymond L. Comenzo, MD, Hani Hassoun, MD

Blood (2014) 124 (21): 3991.

https://doi.org/10.1182/blood.V124.21.3991.3991

Published: 2014

Journal Articles

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph V. Boccia, MD, Stephen J. Noga, MD, PhD, Donald S. Gravenor, MD, Dipti Patel-Donnelly, MD, Robert S. Siegel, MD, Tarun Kewalramani, MD, Edward J. Gorak, DO, MS, Regina A. Swift, RN, Debra Mayo, PharmD, MHA

Blood (2011) 118 (21): 1857.

https://doi.org/10.1182/blood.V118.21.1857.1857

Published: 2011

Journal Articles

Allogeneic NK Cell Therapy After Autologous Stem Cell Transplant: Results of a Phase I Study

Hans-Georg Klingemann, MD, PhD, Carrie Grodman, RN, Andreas K. Klein, MD, Kellie Sprague, MD, Kenneth B. Miller, MD, Tarun Kewalramani, MD, Raymond L. Comenzo, MD, Neng Yu, MD, Marvin Duque, MD, Richard A. Van Etten, MD, PhD, David McKenna, MD

Blood (2010) 116 (21): 4299.

https://doi.org/10.1182/blood.V116.21.4299.4299

Published: 2010

Journal Articles

Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047

Craig H. Moskowitz, MD, Stephen D. Nimer, Andrew D. Zelenetz, MD, PhD, Paul A. Hamlin, Jr., MD, Steven M. Horwitz, MD, Ariela Noy, MD, Carol S. Portlock, MD, David J. Straus, MD, John Gerecitano, MD, PhD, Tarun Kewalramani, MD, Jill M. Vanak, ACNP, Jocelyn C. Maragulia, Joachim Yahalom, MD

Blood (2008) 112 (11): 775.

https://doi.org/10.1182/blood.V112.11.775.775

Published: 2008

Journal Articles

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Alison J. Moskowitz, MD, Stephen D. Nimer, Andrew D. Zelenetz, MD, PhD, Tarun Kewalramani, MD, Jill M Vanak, ACNP, Jocelyn c Maragulia, Joachim Yahalom, MD, Craig Moskowitz, MD

Blood (2008) 112 (11): 776.

https://doi.org/10.1182/blood.V112.11.776.776

Published: 2008

Journal Articles

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Heather Landau, MD, Hani Hassoun, MD, Adam Cohen, MD, Elizabeth Hoover, Tarun Kewalramani, MD, Adam Boruchov, MD, Virginia Klimek, MD, Lillian Reich, MD, Elyn Riedel, Neeta Pandit-Taskar, MD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2008) 112 (11): 3712.

https://doi.org/10.1182/blood.V112.11.3712.3712

Published: 2008

Journal Articles

Relapsed and Primary Refractory Diffuse Large B-Cell Lymphoma: Improving Outcome by Incorporating Involved Field Radiotherapy into a Comprehensive Second-Line High-Dose Therapy Strategy.

Bradford S. Hoppe, MD, Joachim Yahalom, MD, Tarun Kewalramani, MD, Paul A. Hamlin, MD, David Rice, RN, Daniel Filippa, MD, Jocelyn Maragulia, Alandra Weaver, Craig H. Moskowitz, MD

Blood (2007) 110 (11): 1893.

https://doi.org/10.1182/blood.V110.11.1893.1893

Published: 2007

Journal Articles

Outcomes for Patients Who Fail High Dose Chemoradiotherapy and Autologous Stem Cell Rescue for Relapsed and Primary Refractory Hodgkin Lymphoma.

Alison Moskowitz, MD, Joachim Yahalom, MD, Tarun Kewalramani, MD, Manfred Tejerina, Andrew D. Zelenetz, MD PhD, Craig H. Moskowitz, MD

Blood (2007) 110 (11): 1649.

https://doi.org/10.1182/blood.V110.11.1649.1649

Published: 2007

Journal Articles

Late Relapses Characterize Autologous Transplantation (ASCT) in First Complete Remission (CR) for Peripheral T-Cell Lymphoma (PTCL).

Tarun Kewalramani, MD, Steve Horwitz, MD, Andrew D. Zelenetz, MD, PhD, Stephen D. Nimer, MD, Craig H. Moskowitz, MD

Blood (2007) 110 (11): 5110.

https://doi.org/10.1182/blood.V110.11.5110.5110

Published: 2007

Journal Articles

High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.

Hani Hassoun, MD, Brian T. Rafferty, MS, Carlos Flombaum, MD, Vivette D. D’Agati, MD, Virginia M. Klimek, MD, Adam Cohen, MD, Adam Boruchov, MD, Tarun Kewalramani, MD, Lilian Reich, MD, Heather Landau, MD, Stephen D. Nimer, MD, Raymond Comenzo, MD

Blood (2007) 110 (11): 5113.

https://doi.org/10.1182/blood.V110.11.5113.5113

Published: 2007

Journal Articles

Rituximab Maintenance Following High Dose Therapy and Autologous Stem Cell Rescue after RICE Cytoreduction Improves Event Free and Overall Survival

Robert D. Rice, MSN, PhD(c), Craig H. Moskowitz, MD, Tarun Kewalramani, MD, Daniel O. Persky, MD, Brian T. Rafferty, Jocelyn C. Maragulia, Andrew D. Zelenetz, MD, PhD

Blood (2007) 110 (11): 1280.

https://doi.org/10.1182/blood.V110.11.1280.1280

Published: 2007

Journal Articles

Evaluation of Single-Dose Palifermin To Reduce Oral Mucositis (OM) in Fractionated Total Body Irradiation (fTBI) and High Dose (HD) Chemotherapy with Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation.

Thomas C. Shea, MD, Tarun Kewalramani, MD, Yong Mun, Gerald Jayne, Lyndah K. Dreiling, MD

Blood (2006) 108 (11): 3073.

https://doi.org/10.1182/blood.V108.11.3073.3073

Published: 2006

Journal Articles

Relapsed and Refractory Primary Mediastinal Diffuse Large B-Cell Lymphoma: Outcome with ICE-Based Treatment.

Paul A. Hamlin, MD, Mark Dickson, MD, Tarun Kewalramani, MD, Steven M. Horwitz, MD, Carol S. Portlock, MD, Joachim Yahalom, MD, Andrew D. Zelenetz, MD, PhD, Craig H. Moskowitz, MD

Blood (2006) 108 (11): 3057.

https://doi.org/10.1182/blood.V108.11.3057.3057

Published: 2006

Journal Articles

Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.

Raymond L. Comenzo, MD, Ping Zhou, MD, PhD, Hani Hassoun, MD, Tarun Kewalramani, MD, Virginia Klimek, MD, Adam D. Cohen, MD, Susane K. Ferrand, MD, Madhav Dhodapkar, MD, Julie Teruya-Feldstein, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD

Blood (2005) 106 (11): 1156.

https://doi.org/10.1182/blood.V106.11.1156.1156

Published: 2005

Journal Articles

The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL).

Daniel Persky, MD, Carol S. Portlock, MD, Simone Lessac-Chenen, BA, Alexia Iasonos, Ph.D, Andrew D. Zelenetz, MD, Ph.D, Tarun Kewalramani, MD, David Rice, RN, NP-C, Joachim Yahalom, MD, Stephen D. Nimer, MD, Craig H. Moskowitz, MD.

Blood (2005) 106 (11): 2072.

https://doi.org/10.1182/blood.V106.11.2072.2072

Published: 2005

Journal Articles

High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin’s Lymphoma.

Daniel Persky, MD, Julie Teruya-Feldstein, MD, Tarun Kewalramani, MD, Pauline D. Bonner, BA, Alexia Iasonos, Ph.D, David Rice, RN, NP-C, Joachim Yahalom, MD, Stephen D. Nimer, MD, Andrew D. Zelenetz, MD, Ph.D, Craig H. Moskowitz, MD

Blood (2005) 106 (11): 2073.

https://doi.org/10.1182/blood.V106.11.2073.2073

Published: 2005

Journal Articles

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

Steven Horwitz, MD, Craig Moskowitz, MD, Tarun Kewalramani, MD, Paul Hamlin, MD, David Straus, MD, Owen O’Connor, MD, PhD, Ariela Noy, MD, Carol Portlock, MD, Stephen Nimer, MD, PhD, M. Lia Palomba, MD, PhD, Andrew Zelenetz, MD, PhD

Blood (2005) 106 (11): 2679.

https://doi.org/10.1182/blood.V106.11.2679.2679

Published: 2005

Journal Articles

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Madhav Dhodapkar, MD, Adam Cohen, MD, Tarun Kewalramani, MD, Elyn R. Riedel, MA, Cyrus V. Hedvat, MD, Julie Teruya-Feldstein, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2005) 106 (11): 3481.

https://doi.org/10.1182/blood.V106.11.3481.3481

Published: 2005

Journal Articles

The Importance of Molecular Phenotype in Predicting Overall Survival in Patients with Relapsed or Primary Refractory DLBCL Treated with Second-Line Chemotherapy and ASCT.

Craig H. Moskowitz, MD, Tarun Kewalramani, MD, Paul Hamlin, MD, Stephen D. Nimer, MD, Andrew D. Zelenetz, MD, PhD, Julie Teruya-Feldstein, MD

Blood (2004) 104 (11): 10.

https://doi.org/10.1182/blood.V104.11.10.10

Published: 2004

NARROW

Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials

Interim Analysis of a Randomized Phase II Trial Comparing Continuous Lenalidomide and Dexamethasone to Autologous Stem Cell Transplantation in Multiple Myeloma Patients Responsive to Lenalidomide and Dexamethasone Induction

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

Allogeneic NK Cell Therapy After Autologous Stem Cell Transplant: Results of a Phase I Study

Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Relapsed and Primary Refractory Diffuse Large B-Cell Lymphoma: Improving Outcome by Incorporating Involved Field Radiotherapy into a Comprehensive Second-Line High-Dose Therapy Strategy.

Outcomes for Patients Who Fail High Dose Chemoradiotherapy and Autologous Stem Cell Rescue for Relapsed and Primary Refractory Hodgkin Lymphoma.

Late Relapses Characterize Autologous Transplantation (ASCT) in First Complete Remission (CR) for Peripheral T-Cell Lymphoma (PTCL).

High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.

Rituximab Maintenance Following High Dose Therapy and Autologous Stem Cell Rescue after RICE Cytoreduction Improves Event Free and Overall Survival

Evaluation of Single-Dose Palifermin To Reduce Oral Mucositis (OM) in Fractionated Total Body Irradiation (fTBI) and High Dose (HD) Chemotherapy with Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation.

Relapsed and Refractory Primary Mediastinal Diffuse Large B-Cell Lymphoma: Outcome with ICE-Based Treatment.

Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.

The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL).

High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin’s Lymphoma.

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

The Importance of Molecular Phenotype in Predicting Overall Survival in Patients with Relapsed or Primary Refractory DLBCL Treated with Second-Line Chemotherapy and ASCT.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only